Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118


Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):511-4.


Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH.

Drug Alcohol Depend. 2009 Dec 1;105(3):234-9. doi: 10.1016/j.drugalcdep.2009.07.007. Epub 2009 Sep 1.


Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH.

Am J Drug Alcohol Abuse. 2011 Jul;37(4):224-8. doi: 10.3109/00952990.2011.568081. Epub 2011 Mar 28.


Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.


The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.

Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):480-4. doi: 10.1097/QAI.0b013e3182961d31.


Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.

Antivir Ther. 2007;12(6):963-9.


Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.

Douglas Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH.

Am J Drug Alcohol Abuse. 2013 Mar;39(2):80-5. doi: 10.3109/00952990.2013.764885.


Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC.

AIDS. 2005 Jan 28;19(2):145-52.


Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW.

Br J Clin Pharmacol. 2005 Apr;59(4):398-404.


Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S235-46.


Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.

Gutiérrez F, Padilla S, Masiá M, Navarro A, Gallego J, Hernández I, Ramos JM, Martin-Hidalgo A.

Antivir Ther. 2004 Feb;9(1):105-13.


Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):473-82. doi: 10.1097/QAI.0b013e3181eb5ff5.


Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.

King JR, Acosta EP, Yogev R, Wiznia A, Kraimer J, Graham B, Carey V, Britto P, Jean-Philippe P, Moye J, Watson D.

Pediatr Infect Dis J. 2009 Feb;28(2):159-61. doi: 10.1097/INF.0b013e3181861d8b.


Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.

Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G.

Antimicrob Agents Chemother. 2011 Jul;55(7):3195-200. doi: 10.1128/AAC.01598-10. Epub 2011 May 2.


Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM.

Drug Alcohol Depend. 2007 Dec 1;91(2-3):269-78. Epub 2007 Jul 23.


Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

Micheli V, Regazzi M, Dickinson L, Meraviglia P, Villani P, Khoo SH, Viganò P, Cordier L, Cusato M, Duca P, Orlando G, Rizzardini G, Back DJ, Cargnel A.

Ther Drug Monit. 2008 Jun;30(3):306-13. doi: 10.1097/FTD.0b013e318177209e.


Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine.

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.


Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

van der Lee M, Verweel G, de Groot R, Burger D.

Antivir Ther. 2006;11(4):439-45.


Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team.

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.


Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team.

AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.

Supplemental Content

Support Center